Alpha Tau Medical (NASDAQ:DRTS) PT Lowered to $12.00

Alpha Tau Medical (NASDAQ:DRTSGet Rating) had its target price lowered by research analysts at Piper Sandler from $19.00 to $12.00 in a note issued to investors on Wednesday, The Fly reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price target indicates a potential upside of 210.08% from the company’s previous close.

Alpha Tau Medical Price Performance

Shares of DRTS stock opened at $3.87 on Wednesday. The stock has a 50-day moving average of $4.77 and a 200-day moving average of $7.53. Alpha Tau Medical has a 1-year low of $3.75 and a 1-year high of $20.65.

Alpha Tau Medical (NASDAQ:DRTSGet Rating) last released its earnings results on Thursday, August 25th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.07. Research analysts expect that Alpha Tau Medical will post -0.73 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Clear Street LLC bought a new position in Alpha Tau Medical in the first quarter worth approximately $30,000. JPMorgan Chase & Co. bought a new position in Alpha Tau Medical in the second quarter worth approximately $697,000. Ergoteles LLC bought a new position in Alpha Tau Medical in the first quarter worth approximately $146,000. Renaissance Technologies LLC bought a new position in Alpha Tau Medical in the third quarter worth approximately $111,000. Finally, Penserra Capital Management LLC bought a new position in Alpha Tau Medical in the first quarter worth approximately $40,000. Institutional investors own 0.98% of the company’s stock.

About Alpha Tau Medical

(Get Rating)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

See Also

The Fly logo

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.